跳到正文
原文
STAT 主站· Elizabeth Cooney·· 11 天前AI 评分25

ZEUS 和 HORIZON 试验结果:心血管疾病治疗无显著差异

STAT+: Heart association meeting’s readout is trending ‘neutral’

AI 导读

ZEUS 和 HORIZON 两项针对心血管疾病的临床试验均未显示治疗组与安慰剂组之间存在显著差异。这两项研究虽然结果“中性”,但仍提供了宝贵的研究教训。

正文

Trials finding interventions made no difference still teach valuable lessons, experts say

A file photograph of a cardiac monitor displaying a patient's vital signs
Brandon Bell/Getty Images

CHICAGO — If one word could describe research presented at this year’s American Heart Association scientific sessions, it might be “neutral.” 

The meeting began with two blockbuster disappointments, hinted at in top-line results released weeks or months ago but detailed with unvarnished specificity Saturday morning. The ZEUS trial targeting inflammation showed no difference between the treatment and placebo arms. The HORIZON trial taking aim at lipoprotein(a) also revealed nearly identical results, whether participants were on or off the drug.     

In other words, neutral.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

  1. Cardiovascular Disease Reporter

    Liz covers cardiovascular and metabolic disease, asking why we’re not doing better or even losing ground against the world’s leading killer. Send tips on Signal at LizC.22.

来源:STAT 主站 · statnews.com